



UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2024 P 3187-1
Program	Step Therapy - Overactive Bladder
Medication	Mirabegron (generic Myrbetriq®*)
P&T Approval Date	6/2024
Effective Date	8/1/2024

1. Background:

Mirabegron (generic Myrbetriq*) is indicated for the treatment of overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency, either along or in combination with the muscarinic antagonist solifenacin succinate.

Step Therapy programs are utilized to encourage the use of lower cost alternatives for certain therapeutic classes. This program requires a member to try two alternatives prior to coverage for mirabegron.

2. Coverage Criteria^a:

<p>A. Authorization</p> <p>1. Mirabegron (generic only) will be approved based on the following criterion:</p> <p>a. History of failure, contraindication, intolerance, or inadequate response to both of the following:</p> <p>(1) oxybutynin (generic Ditropan or Ditropan XL) (2) solifenacin (generic Vesicare)</p> <p>Authorization will be issued for 12 months</p> <p>^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.</p>
--

*Brand Myrbetriq is typically excluded from coverage.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.

4. References:

1. Myrbetriq [package insert]. Northbrook, IL: Astellas Pharma US, Inc; April 2021.

2. Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. Journal of Urology [Internet]. 2019 Sep 1 [cited 2024 Jun 13];202(3):558–63.
3. Burkhard FC, Bosch JLHR, Lemack GE, et. al. EAU Guidelines on Urinary Incontinence in Adults. European Association of Urology 2020.

Program	Step Therapy – Mirabegron (generic Myrbetriq®)
Change Control	
Date	Change
6/2024	New program